R&D closure is the latest in a series of hits to drug companies.
Pfizer is closing 35% of its global research and development space, according to a 9 November announcement. The New York-based drug company, which employs 14,500 people in research and development worldwide, has said that R&D personnel cuts associated with the closures will make up a significant percentage of the 15% company-wide job cuts planned. Pfizer, which last month acquired US drugmaker Wyeth, has disclosed no further information and did not return phone calls by press time. In early November, US drugmaker Johnson & Johnson announced plans to lay off about 8,000, but did not reveal how the cuts would affect its R&D personnel.
Related links
Related links
Related links in Nature Research
The pharmaceutical industry has had big job losses of late.
Pfizer to buy Wyeth in -billion deal
Related external links
Rights and permissions
About this article
Cite this article
Huge cuts by drug firms. Nature 462, 375 (2009). https://doi.org/10.1038/nj7271-375e
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7271-375e